Details of the BTS

General Information of Binding Target of SBP (BTS) (ID: ST00165)
BTS Name
Somatostatin receptor type 1
Synonyms
SS-1-R; SS1-R; SS1R; SRIF-2
BTS Type
Protein
Family
G-protein coupled receptor 1 family
Gene Name
SSTR1
Organism
Homo sapiens (Human)
Function
Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
UniProt ID
P30872
UniProt Entry
SSR1_HUMAN
PFam
PF00001
Gene ID
6751
Sequence
MFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAIL
ISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLL
RHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLG
VWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAIC
LCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQD
DATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKS
RAYSVEDFQPENLESGGVFRNGTCTSRITTL
Sequence Length
391
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
Evibody anti-Somatostatin receptor CTLA-4R(cys121)Som1 Research Activator N.A. Alzheimer disease [ICD-11: 8A20]
SBP Info
 		[1], [2]
Evibody anti-Somatostatin receptor CTLA-4R-Som1 Research Activator N.A. Alzheimer disease [ICD-11: 8A20]
SBP Info
 		[1], [2]
Evibody anti-Somatostatin receptor CTLA-4R-Som3 Research Activator N.A. Alzheimer disease [ICD-11: 8A20]
SBP Info
 		[1], [2]
Macrocyclic peptide Lanreotide Marketed Inhibitor N.A. Neuroendocrine tumour [ICD-11: XH8DS0]; Acromegaly or pituitary gigantism [ICD-11: 5A60.0]; Graves ophthalmopathy [ICD-11: 9C82.3]; Pituitary cancer [ICD-11: 2D12.Z]; Pancreatic cancer [ICD-11: 2C10.Z]; Gastrointestinal motility disorders
SBP Info
 		[3]
Macrocyclic peptide Octreotide Marketed Inhibitor N.A. Acute pancreatitis [ICD-11: DC31.Z]; Acute and delayed intestinal radiation injury; Pancreatic fistula; Neuroendocrine tumour [ICD-11: XH8DS0]; Acromegaly [ICD-11: 5A60.0]; Polycystic liver disease [ICD-11: DB99.10]
SBP Info
 		[4]
References
1 Engineered protein scaffolds for molecular recognition. J Mol Recognit. Jul-Aug 2000;13(4):167-87.
2 Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides. Proteins. 1999 Aug 1;36(2):217-27.
3 Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist. 2018 Jan;23(1):16-24.
4 Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep. 2016 Jan;18(1):7.